Momelotinib under the microscope: Real-World spleen shrinkage in myelofibrosis

NCT ID NCT07249606

Not yet recruiting Knowledge-focused Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study will observe 93 adults with myelofibrosis who are taking momelotinib as part of their normal care. Researchers will track how well the drug reduces spleen size after 6 months, providing real-world evidence of its effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: momelotinib
What this could lead to: If successful, this study could confirm that momelotinib effectively reduces spleen size in everyday clinical practice, supporting its use for myelofibrosis.
What could go wrong: This is an observational study, not a controlled trial, so results may be less reliable. It is also small (93 people) and not yet recruiting, so findings may not apply broadly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS，MF are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myelofibrosis primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELOFIBROSIS，MF

More trials for these conditions

Other studies related to the condition(s) this trial covers.